Corporate counsel are starting to look over their shoulders.

When the U.S. Securities and Exchange Commission went after Biopure Corp. and its executives for misleading public statements about the U.S. Food and Drug Administration’s review of its products, the biopharmaceutical company escaped without financial repercussions.